Nandita Shangari
Director/Board Member at Capstan Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Laura Shawver | M | 66 |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | 2 years |
Magdalene K. Cook | M | 50 |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | 6 years |
Peter D. Parker | M | 73 |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
David de Graaf | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
Arthur Michael Feldman | M | - |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | - |
Thomas E. Needham | M | 60 |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | 5 years |
Karen Smith | F | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | - |
Haig Aghajanian | M | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | 2 years |
Paul Yaworsky | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 5 years |
Michael Baran | M | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022.
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 3 years |
Lee Cooper | M | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | 2 years |
Brian Hubbard | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
Rajul Jain | M | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | - |
Elizabeth White | M | - |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | 3 years |
Aaron Nelson | M | - |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | - |
Andrew Levin | M | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | - |
David Morris | M | - |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | 8 years |
Andreas Jurgeit | M | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
Karen Smith | M | 56 |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | - |
Rahul Ballal | M | 46 |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | - |
Michal Silverberg | F | 48 |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | 7 years |
Athena Countouriotis | M | 52 |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | 2 years |
Erez Chimovits | M | 60 |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | - |
Laura Brass | M | - |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | 6 years |
Campbell Murray | M | 48 |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | 19 years |
Maina Bhaman | M | 52 |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 1 years |
Isaac Manke | M | 47 |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | - |
Simon Sturge | M | 65 |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | 3 years |
Edward Benz | M | 78 |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | 7 years |
Rajul Jain | F | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 30 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Nandita Shangari
- Personal Network